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Abstract
Background: Type 2 diabetes mellitus (T2DM) comprises the vast majority of all diabetes cases in adults, with
alarmingly increasing prevalence over the past few decades worldwide. A particularly heavy healthcare burden of
diabetes is noted in Europe, where 8.8% of the population aged 20–79 years is estimated to have diabetes
according to the International Diabetes Federation. Multiple risk factors are implicated in the pathogenesis of T2DM
with complex underlying interplay and intricate gene-environment interactions. Thus, intense research has been
focused on studying the role of T2DM risk factors and on identifying vulnerable groups for T2DM in the general
population which can then be targeted for prevention interventions.
Methods: For this narrative review, we conducted a comprehensive search of the existing literature on T2DM risk
factors, focusing on studies in adult cohorts from European countries which were published in English after January
2000.
Results: Multiple lifestyle-related and sociodemographic factors were identified as related to high T2DM risk, including
age, ethnicity, family history, low socioeconomic status, obesity, metabolic syndrome and each of its components, as
well as certain unhealthy lifestyle behaviors. As Europe has an increasingly aging population, multiple migrant and
ethnic minority groups and significant socioeconomic diversity both within and across different countries, this review
focuses not only on modifiable T2DM risk factors, but also on the impact of pertinent demographic and
socioeconomic factors.
Conclusion: In addition to other T2DM risk factors, low socioeconomic status can significantly increase the risk for
prediabetes and T2DM, but is often overlooked. In multinational and multicultural regions such as Europe, a holistic
approach, which will take into account both traditional and socioeconomic/socioecological factors, is becoming
increasingly crucial in order to implement multidimensional public health programs and integrated community-based
interventions for effective T2DM prevention.
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Background
Type 2 diabetes mellitus (T2DM) prevalence has been
increasing rapidly over the past few decades worldwide
[1, 2]. Based on recent International Diabetes Feder-
ation (IDF) estimates, in 2017 there were 451 million
adults (age: 18–99 years) with diabetes globally, a figure
which is predicted to reach 693 million by 2045 [3]. In
the region of Europe alone, 58 million adults are esti-
mated to have diabetes and this number is also ex-
pected to significantly increase to 66.7 million by 2045
(8.8 and 10.2% of the population aged 20–79 years,
respectively), highlighting the heavy healthcare burden
of diabetes in Europe [4]. Moreover, it is estimated that
almost half of all people with diabetes are undiagnosed
(22 million undiagnosed cases in Europe) and, hence,
remain untreated and at significantly greater risk of
T2DM complications [1, 3, 4].
T2DM results from progressive loss of insulin secre-
tion, which is typically combined with various degrees of
insulin resistance [5–7]. An array of risk factors is impli-
cated in the pathogenesis of T2DM, including age, ethni-
city, family history, low socioeconomic status, obesity,
metabolic syndrome, and certain unhealthy lifestyle
behaviors [Table 1] [1, 7–9]. The exact interplay be-
tween these T2DM risk factors represents a complex
pathophysiologic process with intricate underlying gene-
environment interactions, which appear to vary within
different populations [1, 8–10]. As such, research inter-
est has been focused towards studying the pathogenetic
role of various T2DM risk factors and on identifying
vulnerable groups for T2DM which can then be targeted
in clinical practice, prevention interventions and public
health programs [1, 8–13].
In this article, we present a narrative review of key risk
factors and lifestyle behaviors related to high T2DM risk,
with reference to relevant findings from studies in adult
cohorts from European countries. As Europe has an in-
creasingly aging population, multiple migrant and ethnic
minority groups and significant socioeconomic diversity
both within and across different countries [3, 4, 14], this
review is intended to focus not only on modifiable
T2DM risk factors, but also on the impact of pertinent
demographic and socioeconomic factors. For example,
despite being often underestimated, low socioeconomic
status can significantly increase the risk for prediabetes
and T2DM, particularly in high-income countries [15],
thus, becoming increasingly important for assessing
more precisely the risk of T2DM among various Euro-
pean populations. As such, this narrative review provides
a comprehensive overview of key sociodemographic and
lifestyle-related risk factors for identifying vulnerable
groups for T2DM with emphasis on data from Europe.
Methods
Although this paper is not a systematic review, in the
present narrative review we conducted a comprehensive
search of the relevant literature published in English
after January 2000. To this aim, PubMed was searched
using terms relating to T2DM [e.g. diabetes, type 2 (II)
diabetes mellitus (T2DM, DM), non-insulin-dependent
diabetes mellitus (NIDD, NIDDM), and adult-onset
diabetes], T2DM risk factors [e.g. age, BMI, central/vis-
ceral/android obesity, metabolic syndrome, family his-
tory, race/ethnicity, socioeconomic status/position/
indices, SES, low−/middle−/upper-income, poverty,
poor, vulnerable, deprivation, education level and risk
factor], and diabetes-related lifestyle behaviors [e.g. un-
healthy diet, snacking, sweet/soft/fizzy drinks, sugar-
sweetened beverages, whole grains, savory/sweet/salty
snacks, confectionary, fast food, meal/portion size, exer-
cise, physical activity/inactivity, leisure activity, seden-
tary/sitting behavior/time, domestic activities, walking,
outdoor play, computer use/time, gaming, screen time,
reading, and television viewing].
Based on the aforementioned search terms, more than
2250 publications were detected in PubMed, which were
then screened by titles and abstracts. Accordingly, per-
tinent studies with adult cohorts from European coun-
tries, and relevant review articles on the etiology of high
T2DM risk were identified and obtained. The references
of these papers were also hand-searched. In total, more
than 140 publications were identified as relevant to the
scope of this work, and were reviewed in detail. Of
those, 101 publications were included and cited in the
present narrative review, highlighting key lifestyle-
related and sociodemographic risk factors related to
Table 1 List of key risk factors implicated in the pathogenesis
of type 2 diabetes mellitus (T2DM)
Key risk factors implicated in the pathogenesis of type 2 diabetes
mellitus (T2DM)
▪ Increased body weight - overweight or obesity (body mass index,
BMI, ≥25 kg/m2 for Caucasian adults)
▪ Increased abdominal/visceral adiposity - central/android obesity,
increased waist circumference independent of BMI
▪ Other metabolic syndrome components (e.g. hypertriglyceridemia,
low HDL-cholesterol plasma levels, hypertension)
▪ Unhealthy eating/dietary habits (e.g. high consumption of
processed red meat, sugar-sweetened beverages and alcohol, and/or
low consumption of fruits, vegetables, high-fiber and whole grain foods)
▪ Sedentary lifestyle - decreased physical activity
▪ Cigarette/tobacco smoking
▪ Aging (older age)
▪ Race/Ethnicity (non-white ethnic background/ancestry)
▪ T2DM family history (particularly with first degree relatives and
with earlier age of onset)
▪ Genetic predisposition/factors
▪ Gestational diabetes mellitus history
▪ Low socioeconomic status, deprivation
▪ Stress, anxiety and depression
▪ Certain medications (e.g. certain statins and beta-blockers)
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increased T2DM risk in adults with focus on the existing
evidence from Europe.
Results
T2DM risk factors related to obesity and other metabolic
syndrome components
“Diabesity” has been introduced as a new term to better
describe the twin epidemic of T2DM and obesity [16],
since the rising prevalence rates of T2DM during the
past decades have been closely tracking those of obesity
worldwide [1–4, 17]. Obesity is now recognized as the
most important modifiable risk factor for prediabetes
and T2DM, which, depending on the degree, distribu-
tion, timing and duration of excess weight gain, can pro-
gressively lead to a spectrum of metabolic syndrome
manifestations and cardiovascular disease [18]. Of note,
beyond the impact of increasing body mass index (BMI)
on the risk of T2DM, an independent positive associ-
ation has also been clearly documented between central/
visceral obesity and T2DM [16, 18, 19]. As such, visceral
and ectopic (e.g. in the liver, skeletal muscles, and heart)
fat accumulation are now regarded as key contributing
factors to increased T2DM risk, correlating directly with
hyperinsulinemia and insulin resistance [18]. A combin-
ation of underlying mechanisms appears to explain the
higher risk of T2DM with central obesity and ectopic fat
accumulation, primarily relating to dysfunction and a
markedly altered secretion profile of adipocytes in these
fat depots [18]. Indeed, adipocytes in visceral fat depots
are more lipolytic, whilst they also exhibit enhanced
secretion of pro-inflammatory adipokines (e.g. intrerleu-
kin 6 and tumor necrosis factor-α) and decreased secre-
tion of anti-inflammatory adipokines (e.g. adiponectin),
thus, promoting increased insulin resistance and activa-
tion of inflammatory pathways in the adipose tissue, liver
and skeletal muscles [18]. These characteristics of
visceral and ectopic fat deposition contribute to the de-
velopment of the cardio-metabolic complications of
obesity (particularly of central obesity), as has been con-
sistently documented in both basic and clinical research
studies [18].
Obesity - body mass index (BMI)
The relative risk for T2DM in adults rises markedly with
increasing BMI over 30 kg/m2, while it appears to begin
to increase even within the normal BMI range (from 22
and 24 kg/m2 for women and men, respectively) [19, 20].
Multiple studies in Europe have examined the associ-
ation between objectively measured BMI and T2DM,
showing that increased BMI holds a significant positive
association with T2DM [21–25]. In this context, Wanna-
methee et al. have further reported significantly in-
creased T2DM risk with both overweight and obesity
during the 20-year follow-up of the prospective British
regional heart study (7735 men; age: 40–59 years) [23].
Furthermore, BMI has been reported to independently
predict the development of T2DM, with incidence rates
that were approximately three and ten times higher in
individuals with BMI ranging from 25 to 30 kg/m2 and
over 30 kg/m2, respectively [24]. However, it should be
noted that other data show that BMI is not an independ-
ent T2DM predictor [25], indicating that, when variables
such as waist circumference and waist-to-hip ratio
(WHR) are taken into account, central obesity is a better
T2DM predictor [22, 25].
Central obesity - abdominal/visceral fat distribution
A consistent positive association has been documented
between central/visceral obesity and T2DM risk, inde-
pendent of BMI [18, 26, 27]. As aforementioned, this
strong correlation between visceral fat accumulation and
both insulin resistance and hyperinsulinemia is primarily
attributed to a more deleterious secretory, lipolytic and
pro-inflammatory profile of adipocytes in visceral fat
depots [18]. As increased visceral adiposity is now recog-
nized as an independent T2DM risk factor [18], certain
anthropometric indices of central obesity (e.g. waist cir-
cumference, WHR and waist-to-height ratio) are now
applied in clinical practice and research to better assess
the obesity-related risk of T2DM [26–29]. Waist circum-
ference represents the simplest and most extensively
studied among these anthropometric indices, with nu-
merous studies on the relationship between objectively
measured waist circumference and T2DM risk in various
European populations [21, 22, 25–31]. These studies
showed that the prevalence of T2DM rises with increas-
ing waist circumference, and that the latter is a signifi-
cant independent predictor of T2DM development even
after adjusting for BMI [21, 22, 25–31].
Weight gain
Sustained weight gain during various periods of the adult
life appears to further impact on the T2DM risk, with
the results from the European Prospective Investigation
into Cancer and Nutrition (EPIC)-Potsdam Study show-
ing that weight gain in early adulthood (age: 25–40
years) is associated to higher T2DM risk and earlier
T2DM onset compared to weight gain later in life (age:
40–55 years) [32]. Substantial weight gain (> 10%) during
the long-term follow-up of the prospective British re-
gional heart study was also related to increased T2DM
risk [23]. Moreover, the prospective Doetinchem Cohort
Study (1987–2007) showed that a 5-year weight change
in adults (age: 20–59 years) was associated with the
T2DM incidence in the subsequent 5 years, even after
adjustment for the initial BMI [33]. However, in this
Dutch population-based study there was no significant
association between weight change and T2DM after
Kyrou et al. BMC Endocrine Disorders 2020, 20(Suppl 1):134 Page 3 of 13
adjusting for the attained BMI, suggesting that such
weight changes may not exert an independent impact on
the T2DM incidence beyond their effect on the attained
BMI [33].
Other metabolic syndrome components
The association between T2DM risk and additional
metabolic syndrome components (e.g. hypertension and
dyslipidemia) has been also investigated in various Euro-
pean studies [22, 24, 34]. As such, data from studies in
Italy and Greece showed 2- to 3-fold higher T2DM inci-
dence in patients with hypertension (systolic blood pres-
sure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg
or treatment for hypertension) compared to normoten-
sive individuals, further indicating that hypertension is
independently associated with higher T2DM risk [22,
24]. Similarly, these studies also found a positive associ-
ation between dyslipidemia and T2DM [22, 24]. Indeed,
Melidonis et al. reported that fasting triglyceride plasma
levels were independently associated with 3.6-fold in-
creased T2DM risk [22], whilst Bonora et al. showed
that the T2DM incidence was approximately 1.5-fold
higher in individuals with dyslipidemia [defined as fast-
ing triglycerides ≥1.7 mmol/l (150 mg/dl) and/or HDL-
cholesterol ≤1 mmol/l (40 mg/dl) in women or ≤ 0.9
mmol/l (35 mg/dl) in men] compared to those with nor-
mal triglycerides and HDL-cholesterol levels [24].
Overall, it is worth highlighting that the metabolic syn-
drome represents a constellation of independent cardio-
metabolic risk factors, including obesity (particularly
with central/visceral fat deposition), hypertension, dys-
lipidemia, and glucose intolerance, which cluster to-
gether and correlate with higher T2DM and CVD
morbidity and mortality [18]. Indeed, the presence of the
metabolic syndrome appears to result in a 1.5-fold in-
crease in all-cause mortality and a 2-fold increase in
CVD outcomes, whilst it also linked to additional com-
plications, such as obstructive sleep apnea (OSA), non-
alcoholic fatty liver disease (NAFLD) and non-alcoholic
steatohepatitis (NASH), which further contribute to
higher T2DM and CVD risk [18]. Notably, based on
meta-analysis data from 16 cohorts with 42,419 partici-
pants, an average estimated relative risk of 3.5–5.2 was
documented for the association of metabolic syndrome
with incident diabetes, indicating that the metabolic syn-
drome constitutes a key predictor of incident diabetes in
various populations, including Europeans and those of
European descent [35].
T2DM risk factors/behaviors related to diet and physical
activity.
Unhealthy dietary habits, sedentary lifestyle and de-
creased physical activity are closely associated with in-
creased T2DM risk both directly and indirectly through
promoting obesity and various metabolic syndrome
components [Table 1] [1, 8, 9]. As such, lifestyle modifi-
cation that aims to improve dietary habits and increase
physical activity levels constitutes the cornerstone of
T2DM prevention interventions [8]. Indeed, the Finnish
diabetes prevention program resulted in 58% reduced
T2DM risk in overweight adults (40–65 years old) with
impaired glucose tolerance that received individualized
counseling aiming to reduce body weight and both total
and saturated fat intake, as well as to increase fiber in-
take and physical activity [36]. Notably, such interven-
tions have been shown to have sustained long-term
benefits (e.g. healthier dietary habits, and lower body
weight, fasting and postprandial glucose levels) for many
years following the active intervention period [8, 37].
Diet - dietary patterns
Overall, high consumption of sugar-sweetened bever-
ages, processed red meat, refined grains and alcohol, as
well as diets low in fruits, vegetables, fiber and whole-
grain foods are linked to higher T2DM risk [1, 8, 9, 38].
Notably, such associations (e.g. the association between
higher intake of sugar-sweetened beverages and in-
creased T2DM risk) appear to remain significant even
after controlling for BMI [38]. Furthermore, improving
the quality of the carbohydrates and fats in the diet (e.g.
following diets low in glycemic load, glycemic index and
trans fatty acids, and high in cereal fiber, polyunsatur-
ated fatty acids and polyunsaturated-to-saturated fat ra-
tio) appears to favor T2DM prevention, suggesting that
the quality of these macronutrients is also a significant
T2DM risk factor [38]. In addition to the quantity and
quality of macronutrients in the diet, recent interest has
also focused on certain dietary patterns (e.g. the Medi-
terranean diet) which can lower the T2DM risk as part
of a comprehensive dietary approach rather than con-
centrating on single dietary components [39, 40]. The
Mediterranean diet constitutes the traditional dietary
pattern followed during the middle of the previous cen-
tury in olive-growing areas of the Mediterranean region
(e.g. in southern Italy, Spain and Greece), and is charac-
terized by olive oil consumption as the main fat source,
high consumption of plant-based foods and wholegrain
cereals and bread, low-to-moderate consumption of fish,
poultry, dairy products and wine with meals, as well as
low consumption of processed and red meat [40]. A
growing body of evidence from both prospective studies
and randomized controlled trials has shown that higher
adherence to the Mediterranean diet is linked to signifi-
cantly reduced T2DM risk, even after adjustment for po-
tential confounders (e.g. BMI) [40–44]. Moreover,
systematic review data from prospective studies have
shown that adherence to the Dietary Approaches to Stop
Hypertension (DASH) and the Alternative Healthy
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Eating Index (AHEI) may also lower the risk of T2DM
[39], suggesting that such dietary patterns can be also ef-
fective for T2DM prevention [39, 40]. Interestingly, ana-
lyses of data from seven European countries of the
EPIC-InterAct case-cohort study revealed no significant
association between the DASH or AHEI and T2DM risk
after multivariable adjustment which accounted for body
size [45]. However, in this study lower T2DM risk was
noted with adherence to certain reduced rank regression
(RRR)-derived dietary patterns characterized by low in-
take of sugar-sweetened beverages, processed meat, and
refined grains, as well as high intake of vegetables or
fruits [45]. The stronger association of these RRR-
derived dietary patterns to T2DM risk compared to the
DASH and AHEI can be potentially attributed to the fact
that the former were specifically derived to explain varia-
tions in T2DM-relevant biomarkers [45]. In this large
European study with both Mediterranean and non-
Mediterranean countries, adherence to the Mediterra-
nean diet, as assessed by the relative Mediterranean diet
score, was also associated with a small reduction in the
risk of T2DM [46]. Notably, this association was attenu-
ated in adults with age less than 50 years or obesity, as
well as when the olive oil, meat and alcohol components
were excluded from the assessed score [46]. Findings
such as those from the EPIC-InterAct study further
highlight the need to take into account the potential
interplay between multiple factors/behaviors which can
impact on the risk of developing T2DM.
Physical activity - sedentary behaviors/lifestyle
Increased sedentary time and decreased physical activity
levels contribute to high risk of prediabetes and T2DM
[1, 8, 9, 47]. In 2016, based on a pooled analysis of 358
population-based surveys with 1.9 million participants
across 168 countries, the global age-standardized preva-
lence of insufficient physical activity was 27.5%, with
even higher prevalence in women and high-income
countries [48]. Recent data based on objectively mea-
sured physical activity and sedentary behaviors showed
that the vast majority (> 95%) of the adults in the EPIC-
Norfolk Study (1259 participants; age: 49–91 years) were
insufficiently active, with increasing sedentary time and
decreasing total, light- and moderate-to-vigorous phys-
ical activity over time [49]. In this study, correlates of
higher rates of the increase in sedentary time and the
decrease in physical activity included both higher BMI
and older age in men and women [49]. Combating such
alarming trends is an important component of T2DM
prevention, particularly in individuals at high T2DM risk
[47]. Overall, a recent Cochrane systematic review of
randomized controlled trials with duration of at least
two years showed that combining diet with increased
physical activity delays the development and reduces the
risk of T2DM in adults with impaired glucose tolerance
[50]. However, further evidence is still needed regarding
the impact of physical activity alone [50]. Furthermore,
data from the ProActive UK trial in adults with T2DM
family history showed that objectively measured moder-
ate- and vigorous-intensity physical activity predicted
insulin resistance independent of sex, age, waist circum-
ference, smoking status, self-reported TV viewing and
time spent sedentary and at light-intensity activity; thus,
highlighting the benefits of promoting at least moderate-
intensity physical activity (e.g. brisk walking) on insulin
sensitivity in such high-risk populations [51]. As such,
structured lifestyle interventions which include at least
150 min of regular moderate-to-vigorous physical activ-
ity per week and dietary changes aiming in 5–7% weight
loss are recommended in order to delay or prevent
T2DM in adults at high T2DM risk [47]. Moreover, a
population-based study in middle-aged adults with 5.6
years of follow-up (Medical Research Council Ely study,
1994–2003) showed that objectively measured sedentary
time may also predict insulin resistance at follow-up,
even after adjustment for moderate- and vigorous-
intensity physical activity levels, and independently of
baseline age, sex, fat mass, smoking status, fasting insulin
levels and follow-up time [52]. Thus, reducing sedentary
behaviors, which are characterized by energy expenditure
of ≤1.5 metabolic-equivalent units and are conducted in
sitting, reclined or lying down positions (e.g. television
viewing and desk work), is also recommended as an add-
itional measure on top of structured exercise in order to
further decrease the risk of developing T2DM [47].
T2DM risk factors related to socio-demographic
parameters
Taking into account non-modifiable T2DM risk factors
(e.g. age, family history and ethnicity), as well as
socioeconomic-related parameters, is an integral part of
the risk assessment process to effectively identify indi-
viduals and sub-group populations at high T2DM risk
which should be targeted for intensive interventions and
prevention programs [1, 9, 53].
Aging - older age
Life expectancy has been rising in most countries, with
the global life expectancy at birth having increased from
65.6 years in 1990 to 73 years in 2017 [54]. After super-
imposing these trends for progressively aging popula-
tions worldwide to the global diabesity epidemic and the
recent advances in the survival of patients with diabetes,
it is no surprise that older age is now recognized as an
increasingly crucial T2DM risk factor [2–4, 54, 55].
Aging increases the risk of developing T2DM by both
impairing insulin secretion and enhancing insulin resist-
ance through obesity and sarcopenia [55]. In addition,
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increasing age has also been shown to independently
predict lower daily physical activity levels [56], with the
rates of insufficient physical activity, increasing seden-
tary time and decreasing physical activity being more
pronounced among older adults [47]. Currently, older
adults (age: ≥65 years) exhibit the highest T2DM preva-
lence among any age-group, whilst the diabetes cases in
this age-group worldwide are expected to increase from
122.8 million in 2017 to 253.4 million in 2045 [3].
Based on the diabetes prevalence data by World Bank
income group and age, middle- and high-income coun-
tries exhibit the highest diabetes prevalence in the 60–
74 (19%) and 75–79 (22%) age-group, respectively,
while in low-income countries the peak diabetes preva-
lence (8%) is documented in the 55–64 age-group [3].
Of note, high-income countries appear to have 3-fold
higher diabetes prevalence among the 65–69 age group
compared to low-income countries [3]. Particularly in
Europe, where the general population aged 50–99 years
is projected to reach 53.6% by 2045 (45.1% in 2017),
aging is considered a key driver of the T2DM epidemic
which accounts for a large proportion of the current
(19.4%, 28.5 million cases in 2017) and projected
(19.8%; 43.9 million cases in 2045) high diabetes preva-
lence among people older than 65 years [4]. This associ-
ation between aging and T2DM has been confirmed in
both men and women by multiple European cross-
sectional and longitudinal studies, which have consist-
ently showed that age is an important T2DM predictor
with significantly higher T2DM prevalence with in-
creasing age [4, 22, 24, 25, 30]. Finally, although Europe
exhibits one of the lowest proportion of undiagnosed
diabetes cases (37.8%) worldwide, a large number of
older adults with diabetes remains undiagnosed [3, 4],
whilst many older adults with diabetes who receive care
at home are also unaware of their diagnosis [57].
Diabetes family history
Family history of T2DM is recognized as a crucial non-
modifiable T2DM risk factor, constituting an easily
assessed marker of the underlying T2DM genetic predis-
position [1, 58, 59]. Indeed, multiple studies with Euro-
pean cohorts reported that T2DM family history is an
independent predictor of T2DM in both men and women
[22, 25, 59–63]. Notably, data from six European countries
of the EPIC-InterAct study showed that T2DM family
history was strongly associated with the T2DM risk, with
most of this risk remaining unexplained even after ac-
counting for key anthropometric, lifestyle and genetic
T2DM risk factors (e.g. BMI, waist circumference, physical
activity and a multi-SNP genetic risk score) [59]. Further-
more, analyses from the Dutch contribution to the EPIC
study (EPIC-NL; 35,174 adults; age: 20–70 years; median
follow-up:10.2 years) documented a positive association
between both paternal and maternal diabetes history and
increased T2DM risk, independent of lifestyle, diet and
adiposity [60]. Based on these data, history of maternal
diabetes conferred slightly higher T2DM risk compared to
paternal, due to larger contribution of lifestyle factors, diet
and adiposity [60]. Interestingly, in two population-based
cross-sectional surveys on T2DM in Finland and China
(FINRISK 2002 Study and the Qingdao Diabetes Preven-
tion Program, respectively) which are included in the
DECODE-DECODA collaboration (Diabetes Epidemi-
ology: Collaborative Analysis of Diagnostic Criteria in Eur-
ope and Asia), the synergistic effect of diabetes family
history with obesity on the prevalence of T2DM was
significant only in Finnish men and not in the Chinese
cohort [61]. Moreover, findings from a large cohort of 60-
year old men and women from Sweden suggest that
history of parental diabetes in combination with obesity
appears to be particularly hazardous in men by synergis-
tically increasing the risk of developing T2DM [62]. It is
also noteworthy that, the Botnia Study in Finland (5810
individuals from 942 families) reported that the strongest
T2DM heritability was identified in patients with onset
age between 35 and 60 years [64]. Overall, there is now
compelling evidence from studies with family and twin co-
horts that genetic factors strongly impact on the T2DM
risk, whilst a rapidly increasing body of large genome-
wide association studies (GWAS) has identified over 300
genetic variants which are strongly associated with T2DM
[1, 65]. However, due to the highly complex and polygenic
T2DM nature, these explain only a fraction of the T2DM
heritability, while the rest could be attributed to other fac-
tors (e.g. gene-environment interactions between T2DM-
related genetic loci and environmental exposures/determi-
nants) [1, 5]. In fact, recent analysis within the EPIC-
InterAct study across eight European countries has shown
that the genetic susceptibility to T2DM, insulin resistance
and BMI did not modify the association between macro-
nutrient intake and incident T2DM, suggesting that the
macronutrient intake recommendations for T2DM pre-
vention do not require further adjustment for differences
in this genetic predisposition [66]. Similarly, recent data
from the Malmö Diet and Cancer cohort showed that
both a genetic-based and a diet-based T2DM risk score
were associated with increased T2DM incidence, but
apparently in an independent way, thus supporting the
notion that individuals at either high or low genetic risk
would benefit from favorable diet choices [67].
Ethnicity: Ethnicity constitutes an additional non-
modifiable T2DM risk factor, with certain ethnic groups
exhibiting inherently higher T2DM risk regardless of the
country of residence [1, 9, 18, 68]. Apart from differences
in lifestyle and socioeconomic related parameters, these
ethnic-related disparities in the T2DM prevalence are
attributed to higher T2DM genetic predisposition and
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enhanced susceptibility for cardio-metabolic complica-
tions in relationship to body composition, central fat dis-
tribution and obesity [1, 18, 68–70]. As such, significantly
higher risk for insulin resistance and T2DM has been
noted in South Asian, Chinese and Japanese individuals
with overweight or obesity compared to weight-matched
controls of Caucasian origin [68–73]. In Europe, several
studies have investigated the prevalence of T2DM in mi-
grant and ethnic minority groups compared to European
host populations, with the accumulated evidence consist-
ently showing higher T2DM prevalence among the former
groups [68, 72–79]. For example, in the UK the T2DM
prevalence among minority ethnic communities is ap-
proximately 3- to 5-fold higher than in the white British
population, with earlier onset by 10–12 years and a signifi-
cant proportion of T2DM patients aged less than 40 years
[73]. Overall, systematic review and meta-analysis data
have shown that the T2DM risk among ethnic minority
groups living in Europe is higher compared to European
host populations and varies according to their geograph-
ical origin [68]. Specifically, the groups of South Asian,
Sub-Saharan African, and Middle Eastern/North African
origin exhibit, respectively, 3- to 5-fold, 2- to 3-fold, and
2- to 4-fold higher T2DM risk (higher for women than for
men) [68]. Furthermore, among the South Asian sub-
groups, Bangladeshi had the highest T2DM risk compared
to Europeans, followed by Pakistani and then Indians [68].
Based on nationwide data on the asylum seekers who
arrived in the Netherlands from 2000 to 2008, higher
T2DM risk has been reported in asylum seekers (aged 20–
79 years) from most of the origin countries (particularly
from Somalia, Sudan and Sri Lanka) compared to the gen-
eral Dutch population [79]. Such data are becoming
increasingly pertinent, since a growing burden of diabetes
in migrant minority populations is now posing a public
health challenge in several European countries, while the
migration flow of people into Europe is not expected to
slow down soon as it is driven by both “pull-factors” in
host countries (e.g. job opportunities and better well-
being) and “push-factors” in native/origin countries (e.g.
food shortage, economic crisis, terrorism and wars) [14].
In this context, it becomes evident that policy initiatives
and public health programs for T2DM prevention should
further take into account the ethnic-related differences in
T2DM risk among the increasingly diverse populations
within and across different countries.
Socioeconomic status
Low socioeconomic status (SES), assessed mainly based
on income, occupation and educational level, is an inde-
pendent T2DM risk factor [Table 1] [9, 15, 80–84]. Sys-
tematic review and meta-analysis data have shown that
increased T2DM incidence is associated with low SES in
high-, middle- and low-income countries [15]. Notably,
the strength of this association was consistent in high-
income countries, but further evidence is needed for
low- and middle-income countries [15], since for the
latter there are also data suggesting higher T2DM preva-
lence in high SES groups [80]. The exact mechanisms
linking low SES to increased T2DM risk are still under
investigation, with key modifiable T2DM factors (e.g.
obesity, diet, physical activity and alcohol intake)
accounting for 33 to 50% of this association [83]. The
remaining part may be attributed to various other
factors relating to psychosocial stress, hopelessness,
material deprivation, restricted autonomy, and limited
access to healthy food, exercise facilities and health
services [83–85].
In Europe, the significance and magnitude of the asso-
ciation between deprived SES and T2DM vary depend-
ing on the study, with part of these inequalities
explained by SES differences in the prevalence of trad-
itional T2DM risk factors [85]. A large French survey
(32,435 men and 16,378 women, age: 35–80 years) inves-
tigated the relationship between T2DM and SES, as
assessed by the EPICES score which accounts for the
multidimensional material, psychological and social
aspects of deprivation [86]. The findings of this study
showed higher risk of T2DM onset among deprived men
and women compared to non-deprived subjects, even
after accounting for age, and lifestyle, clinical and bio-
logical variables [86]. Another cross-sectional and longi-
tudinal study in 11 European countries in 2004 and
2006 (21,323 men and women, aged ≥50 years) revealed
that only women had significant inequalities in the
T2DM prevalence and incidence as a function of SES,
which were mediated by BMI [87]. Indeed, the available
evidence in Europe suggests that the SES inequalities in
T2DM tend to be greater and more consistent in women
compared to men [85, 88]. Moreover, a cross-sectional
study in middle-aged Swedish adults (3128 men and
4821 women, age: 35–56 years) showed that the associ-
ation between T2DM and low SES early in life (fathers’
occupation and participants’ education) disappeared
after adjusting for the adult SES (participants’ occupa-
tion) and adult T2DM risk factors [89]. However, sys-
tematic review data indicate that childhood SES is
associated with T2DM in later life, since this association
remains despite the fact that adjustment for adult SES
and obesity tends to attenuate the T2DM risk attributed
to childhood SES [90].
It should be also highlighted that, cross-sectional data
from five German population-based studies (11,688 men
and women, age: 45–74 years) showed a stepwise in-
crease in T2DM risk with increasing regional area
deprivation, independent of individual SES [91]. Interest-
ingly, the long-term follow-up of the “Moving to Oppor-
tunity” project, which was a social experiment designed
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and implemented by the US Department of Housing and
Urban Development, revealed that moving from a high-
to a lower-poverty neighborhood was associated with
modest, but potentially important decrease in the preva-
lence of both diabetes and extreme obesity [92]. Further-
more, findings from the 2002 Oslo Health Study suggest
that the residential location (organization of urban space
and spatial distribution of health-related resources) of
individuals is a highly significant and independent
T2DM predictor even after adjusting for multiple covari-
ates (e.g. age, BMI and ethnicity) [93]. Thus, living in the
east side of Oslo, which is a disadvantaged and densely
populated area associated with social stigma and immi-
gration, was found to increase the odds of T2DM by ap-
proximately 60% [93]. In this study, the positive
association between T2DM and ethnicity was, at least,
partly mediated by the local sociospatial/environmental
setting [93]. Another study from Sweden also reported
high T2DM prevalence in a socially vulnerable neighbor-
hood, independent of the country of origin (Sweden or
Iraq) [94]. Similar data have been also reported in the
US, with the community-based Boston Area Community
Health epidemiologic survey (5503 Boston residents,
aged 30–79 years) revealing that the SES holds a more
potent association with diabetes prevalence compared to
ethnicity [95]. On the other hand, data from Australia
have shown that all migrant groups exhibit higher
T2DM prevalence compared to the Australian-born
population across all SES strata [96]. As such, there is a
growing need for further research into the sociodemo-
graphic factors related to high T2DM risk, which will
take into account not only aging and ethnicity, but also
the broader socioeconomic and socioecological determi-
nants of prediabetes and T2DM [82, 83].
Discussion
Currently, there are several clinical practice guidelines
for T2DM screening and prevention which are endorsed
by national and international organizations [97]. Accord-
ingly, in clinical practice testing of adults for prediabetes
and T2DM is typically performed based on predefined
screening criteria related to established T2DM risk fac-
tors, such as those recommended by the American Dia-
betes Association (Table 2) [7]. Furthermore, numerous
non-invasive risk scores (e.g. the Finnish diabetes risk
score, FINDRISC), as well as extended models which
additionally include biomarkers, have been developed in
order to identify adults at high T2DM risk in the general
population [10–12, 53]. Indeed, most non-invasive risk
scores can identify individuals at high risk of developing
T2DM within the subsequent 5- to 10-year period, with
prediction models which include biomarkers performing
slightly better [11]. However, most of these models may
overestimate the actual T2DM risk [11], whilst data from
the EPIC-InterAct study regarding non-invasive T2DM
prediction models developed in populations of European
ancestry showed that the performance of each model
varies depending on age, sex, adiposity and country [98].
Moreover, it is important to highlight that, so far, the
prevailing approach for T2DM prevention has been
implementing a medical model for identifying and
treating individuals at high T2DM risk through pri-
marily one-by-one programs/interventions within the
healthcare system [82, 83]. However, this model is con-
sidered to underestimate the complexity and scale of
diabesity and fails to address vital underlying factors
(e.g. low SES, deprivation and psychosocial stress)
which increasingly fuel this problem [82, 83]. This is
also clearly reflected in the disproportionate paucity of
interventions aimed against fundamental social, eco-
nomic and environmental factors which have been
implicated in the current T2DM and obesity epidemic.
Therefore, a broader strategic approach is required in
order to confront the problem of T2DM prevention
both at the individual and the societal level through a
collaborative effort which will mobilize a wider range of
stakeholders/partners (Fig. 1) [53].
Considering the current trends regarding aging, demo-
graphic structure, migration, and socioeconomic diver-
sity across multinational and multicultural regions like
Europe, this holistic approach is becoming increasingly
essential in order to put into effect multidimensional
public health programs and integrated interventions for
Table 2 Current criteria for testing for prediabetes or type 2
diabetes mellitus (T2DM) in asymptomatic adults, as
recommended by the American Diabetes Association (ADA) [7]
ADA-recommended criteria for testing for prediabetes or T2DM in
asymptomatic adults
1. Testing should be considered in adults with body mass index (BMI)
≥25 kg/m2 (or ≥ 23 kg/m2 in Asian Americans) who have at least one of
the following risk factors:
(i) First-degree relative with diabetes
(ii) Race/ethnicity related to high T2DM risk
(iii) History of cardiovascular disease
(iv) Hypertension (≥140/90mmHg or on treatment for hypertension)
(v) HDL-cholesterol plasma levels < 35 mg/dL (0.90 mmol/L) and/or
triglyceride plasma levels > 250mg/dL (2.82 mmol/L)
(vi) Physical inactivity
(vii) Women with polycystic ovary syndrome (PCOS)
(viii) Other clinical conditions associated with insulin resistance (e.g.
acanthosis nigricans)
2. Annual testing should be performed in patients with prediabetes [i.e.
impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or
HbA1C ≥5.7% (39 mmol/mol)]
3. Lifelong testing at least every 3 years should be performed in women
who were diagnosed with gestational diabetes mellitus (GDM)
4. Testing should begin at the age of 45 years for all other individuals
5. If results are normal, testing should be repeated at least every 3 years,
with consideration for more frequent testing depending on the initial
results and risk status.
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effective T2DM prevention which will take into account
both traditional and socioeconomic/socioecological fac-
tors. The EU-funded Feel4Diabetes study represents
such an integrated approach, as it developed and imple-
mented a school and community-based intervention
which promoted healthy eating and active lifestyle for
T2DM prevention in vulnerable families across six Euro-
pean countries (more than 12,000 families in Bulgaria,
Hungary, Belgium, Finland, Greece and Spain) [13]. This
was implemented through the provision of a supportive
social and physical environment at multiple levels (i.e.
home, school and municipality), as well as lifestyle coun-
seling to the identified parents at high T2DM risk [13].
Of note, to make community-based approaches more
cost-effective a two-stage screening process can be ap-
plied, initially targeting low SES groups and regions/mu-
nicipalities with known higher prevalence of such groups
(e.g. based on documented unemployment rates, income
and education levels) which will be selectively screened
with non-invasive scores (e.g. the FINDRISC). Sub-
sequently, those individuals/families identified at high
T2DM risk would be referred to local health centers for
clinical screening/testing and interventions against
modifiable T2DM risk factors. Overall, such multidi-
mensional approaches for the prevention of T2DM may
have a broader impact against the current diabesity epi-
demic within and across countries in Europe.
Conclusions
In concluding this review, it is also important to ac-
knowledge certain limitations of this work. As such,
although we employed an effective bibliographic search
strategy which aimed at reducing the bias in the selec-
tion of the reviewed articles, it should be acknowledged
Fig. 1 Prevention of type 2 diabetes mellitus (T2DM) in the context of a broader collaborative effort which mobilizes multiple partners/
stakeholders at a national and international (e.g. European) level (adapted from Lindström et al. 2010 [53])
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that not all relevant published papers have been included
in this narrative review. However, the scope of this work
was not to present an exhaustive list of all the relevant
published studies or a systematic review on T2DM risk
factors, but rather to provide a narrative overview of the
relevant literature regarding key lifestyle-related and
sociodemographic T2DM risk factors, particularly since
the latter are often neglected. Furthermore, the emphasis
of this specific work was placed on data from Europe
which represents a region with high T2DM prevalence
in combination with an increasingly aging population,
multiple migrant/ethnic minority groups and significant
socioeconomic diversity. Hence, although the aforemen-
tioned T2DM risk factors pose a global problem, it must
be acknowledged that not all the findings/conclusions
from the studies included in this review can be directly
extrapolated and utilized to describe the exact associ-
ation between each one of these risk factors and T2DM
within the specific context of other regions of the globe.
Finally, examining the contribution of the aforemen-
tioned risk factors to the complex pathophysiology of
T2DM in children and adolescents was beyond the
scope of the present review. Thus, readers with a specific
interest in the growing problem of T2DM in children
and adolescents, which appears to disproportionately im-
pact ethnic/racial minorities, are encouraged to further
consult additional reviews and consensus reports dedi-
cated to this specific topic [99–101].
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